Vanessa

• Conditions: The study population is intended to follow the real-world use of systemic therapy. Eligible patients with either eTNBC or mTNBC will be enrolled consecutively; it is anticipated that sufficient numbers of eTNBC and mTNBC will be achieved with sequential enrollment in as many sites as needed and no stratification will be performed.; ALL SOLID TUMORS; D48.9

• Registration Number: LBCTR2021124932
• Lead Sponsor: F. HOFFMANN-LA ROCHE LTD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-12-31
• Study Start: 2024-04-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients must meet the following criteria for enrolment in this registry:
- Patient is an adult (according to age of majority as defined by local regulations)
- Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the disease, at the enrolment date (informed consent date)
- Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date, irrespective of the availability of test results
- Informed consent has been obtained from the patient or legally authorized representative, as per local regulations

Exclusion Criteria

Patients who meet the below exclusion criterion at the time of enrolment will not be enrolled in this registry:
- Patient has a prior or current diagnosis of hematological malignancy

Study & Design

• Study Type: Observational
• Study Design: Not specified